Shares of GeoVax Labs, Inc. (NASDAQ:GOVX – Get Free Report) have received an average recommendation of “Buy” from the seven research firms that are presently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $14.20.
Separately, D. Boral Capital reaffirmed a “buy” rating and set a $18.00 price target on shares of GeoVax Labs in a research report on Thursday, February 27th.
Get Our Latest Stock Analysis on GeoVax Labs
Institutional Investors Weigh In On GeoVax Labs
GeoVax Labs Stock Performance
GeoVax Labs stock opened at $1.54 on Friday. The business’s 50 day simple moving average is $1.85 and its 200 day simple moving average is $2.33. GeoVax Labs has a 12 month low of $1.09 and a 12 month high of $11.18.
GeoVax Labs Company Profile
GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.
See Also
- Five stocks we like better than GeoVax Labs
- What Are Dividend Achievers? An Introduction
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What is the Nasdaq? Complete Overview with History
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Airline Stocks – Top Airline Stocks to Buy Now
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.